ReviewSeminars in interventional radiology2019
Ablation plus Transarterial Embolic Therapy for Hepatocellular Carcinoma Larger than 3 cm: Science, Evidence, and Future Directions.
Review in Seminars in interventional radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Trans-Arterial Chemoembolization Combined with Microwave Ablation versus Microwave Ablation Alone for 3-5 cm Hepatocellular Carcinoma: A Multicenter Retrospective Study.Journal of hepatocellular carcinoma · 2026Article
- China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).Liver cancer · 2025Article
- Comprehensive treatment of intermediate and advanced primary hepatocellular carcinoma based on transcatheter arterial chemoembolization (Review).Oncology letters · 2025Review
- Proceedings from an international consensus meeting on ablation in urogenital diseases.Insights into imaging · 2024Article
- [Guidelines for image-guided ablation of primary liver cancer (2023 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition).Liver cancer · 2023Article
- Bench-to-bedside development of multifunctional flexible embolic agents.Theranostics · 2023Review
- Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?World journal of gastrointestinal oncology · 2021Review
- Image-Guided Peri-Tumoral Radiofrequency Hyperthermia-Enhanced Direct Chemo-Destruction of Hepatic Tumor Margins.Frontiers in oncology · 2021Article
- Percutaneous Radiofrequency Ablation for Liver Tumors: Technical Tips.Interventional radiology (Higashimatsuyama-shi (Japan) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thermal ablation is widely regarded as definitive therapy for early-stage hepatocellular carcinoma, but its efficacy decreases in tumors greater than 3 cm. Extensive clinical studies have supported improved outcomes provided through combining transarterial embolic therapy with ablation in the treatment of larger tumors. This article will provide a survey of the science and data for combination therapy in both thermal and nonthermal ablation modalities, as well as describe emerging applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.